Frank W. Roemer
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
Articles (10)
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Objective To investigate which magnetic resonance imaging (MRI)–based articular pathologies are predictive of subsequent medial femorotibial compartment quantitative cartilage thickness loss and therefore suitable for enrichment of clinical trials with participants showing a high likelihood for structural progression. Methods Semiquantitative MRI Osteoarthritis Knee Score (MOAKS) assessments at baseline and quantitative cartilage thickness measurements at baseline and year‐2 follow‐up were performed in 599 participants (age 62 years; body mass index 31 kg/m 2 ; 59% female) from the Osteoarthritis Initiative–based Foundation for the National Institutes of Health Osteoarthritis Biomarkers Consortium. Knees were classified as medial femorotibial compartment (MFTC) progressors or nonprogressors based on MFTC cartilage thickness change (smallest detectable change threshold −111 μm). Logistic regression was used to investigate the association between baseline presence and severity of MFTC MOAKS pathologies with subsequent MFTC progression. The standardized response mean (SRM) was computed to estimate the sensitivity to change that can be achieved when selecting knees based on MOAKS pathologies. Results Presence of MFTC MOAKS cartilage damage (odds ratio [OR] 2.77 [95% confidence interval (95% CI) 1.76, 4.36]), MFTC bone marrow lesions (OR 2.69 [95% CI 1.89, 3.83]), medial meniscus extrusion or damage (OR 2.21 [95% CI 1.37, 3.55]), as well as MOAKS severity subscales for cartilage and meniscus damage were associated with subsequent progression. The SRM was greater in knees with than in knees without the presence of these pathologies and was associated with the severity of those pathologies. Conclusion MRI‐based grading of articular pathologies makes it possible to specifically select progressor knees suitable for inclusion in clinical trials but also to identify knees in which treatment is not indicated (e.g., knees without cartilage damage despite presence of radiographic osteoarthritis).
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (13)
Rafael Heiss
University Hospital Erlangen
Kerry Costello
Assistant Professor
University of Florida
David Felson
The University of Manchester
Ali Guermazi
Professor
Boston University
David J Hunter
University of Sydney
Shadpour Demehri
Associate Professor
Johns Hopkins University
Deepak Kumar
Assistant Professor (Secondary appointment)
Boston University School of Medicine
S. Reza Jafarzadeh
Assistant Professor
Boston University School of Medicine
Vijaya Kolachalama
Associate Professor
Boston University
Zong-Ming Li
-
Neil Segal
Professor
University of Kansas Medical Center
Cara Lewis
Associate Professor
Boston University
Leena Sharma
Chang-Lee Professor
Northwestern University Feinberg School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.